Skip to content
‹ Back to IndustriesSciences

Overcoming Problems with Hybrid Rocket Engines is Key to Launching Us Further into Space

Hybrid rocket engines combine elements of both liquid and solid propulsion systems to offer improved efficiency, safety, and control compared to traditional rocket technologies. Advances in hybrid propulsion are seen as a key enabler for more accessible and cost-effective space exploration. Greater accessibility to space could accelerate scientific discovery and technological innovation.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · HybridRobert FabianRocket EnginesSpace
Share

Key takeaways

01

Hybrid rocket engines offer a middle ground between liquid and solid propulsion, providing better control and safety.

02

Improved rocket technology lowers barriers to space exploration for commercial and scientific missions.

03

Ongoing development of hybrid engines could unlock new opportunities for deep space travel and research.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Hybrid isn’t just the word with us earthlings, it’s also the next big thing in space technology. Hybrid rocket engines have been developed to increase efficiency and control over more established liquid and solid rocket engines. With better rocket technology comes more accessible space exploration, meaning the potential for scientific discoveries and technological advancements grows exponentially. In fact, according to a report by Morgan Stanley, the global space industry could be worth $1.1 trillion or more by 2040.

Still, while hybrid rockets offer certain advantages over the more traditional rockets, they also come with several drawbacks, including the fact that refueling hybrid rockets is more challenging than refueling liquid and solid rockets. Large hybrid orbital rockets also require turbopumps, but turbopumps can’t use the same fuel and oxidizer as in liquid-propellant rockets. Finally, there hasn’t been as much research on hybrid rockets as with other rockets, so many of their problems have not been fully addressed.

Private aerospace company Vaya Space has been making waves in the industry with its revolutionary Vortex hybrid engine technology. Robert Fabian, the company’s Chief Operating Officer, offers deeper insights into this new technology and its potential impact on space travel.

Robert’s Thoughts:

“What makes Vaya Space unique really is our engine technology, what we call the Vortex hybrid engine. We’ve taken the historical problems of hybrid engines and core performance and combustion instability and solved them, producing an engine that’s significantly cheaper, significantly simpler, and significantly safer than anything else out there on the market.

When I first heard about this technology, I didn’t believe it. I had to do the math myself to make sure it would work, and I’ve watched it go from math on a page and a concept to lab scale tests, to larger engine tests, to flight tests, and I’m really looking forward to seeing the production engine for our Dauntless launch vehicle fire for the first time.”

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Clinical data harmonization is the bottleneck for life sciences AI

Clinical data harmonization is the bottleneck for life sciences AI

Life sciences companies moving AI from experimentation to scale keep running into messy trial data. One study can draw on EDC, health records, eCOA tools, wearables and imaging, and data teams at pharma SMEs often spend up to 80% of their time wrangling it. Commentators point to lakehouse architectures and data-cleansing AI agents, though the agents are still at proof of concept.

  • 01Treat automation gains as proof-of-concept for now; evaluate AI/harmonization choices based on data readiness, governance, and whether the architecture supports traceability and regulatory needs.

Sep 26, 2026

CDMOs’ new capacity skews stainless by liters, but single-use leads by system count

CDMOs’ new capacity skews stainless by liters, but single-use leads by system count

Contract Pharma reports bioTRAK data projecting CDMOs will install roughly 120 bioreactors by 2030. It says 71% of added volume is large-scale stainless steel, while 61% of systems are single-use.

  • 01Utilization discipline is still driving builds: BioTRAK’s Dawn Ecker told Contract Pharma expansion conversations typically start after a site is booked above ~80% for several years.

Sep 22, 2026

Pharma supplier diversification means little if every supplier uses the same airport

Pharma supplier diversification means little if every supplier uses the same airport

Biocair's Patrick Wohl argues in Pharmaceutical Commerce that life sciences firms must map airports, sea lanes, customs gateways and carriers alongside suppliers. Suppliers spread across countries can still share one air hub. The fix he describes is pre-qualified alternate routes and continuous review, with clinical trial shipments and cold-chain medicines the first cargo exposed when a corridor closes.

  • 01A supplier base spread across several countries can still be a single point of failure if every shipment routes through one airport hub or corridor; the sharper question for a logistics provider is which hubs each qualified lane actually depends on.
  • 02Gartner data cited by MD+DI gives a benchmark: 42% of procurement leaders rank supply disruption as their organization's top risk, with geopolitical issues including tariffs and regulatory changes ranking third.
  • 03A route map ages fast. Pharmaceutical Commerce published the mapping argument on July 24 and was reporting fresh Red Sea and Iran-related freight risk for pharma lanes by Aug. 10, which is the case for treating mapping as a recurring review rather than a project.

Sep 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512